13F reference period
Q2 2026
Security Snapshot
Eikon Therapeutics, Inc. - COMMON STOCK (EIKN) Institutional Ownership
CUSIP: 282564103
13F Institutional Holders and Ownership History from Q1 2026 to Q3 2026
Institutions Reporting
77
Shares (Excl. Options)
26.49M
Full value: 26,490,842 · shares · 30 Jun 2026Price
$13.05
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- EIKN on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 26,490,842
- Total 13F value
- $344,120,783
- Portfolio coverage rank
- 0%
- Share change
- +2,739,220
- Value change
- +$39,361,862
- Number of holders
- 77
- Shares outstanding
- 54,119,137
- SEC-reported price per share
- $8.04
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- EIKN - Eikon Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 282564103.
- 77 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 52 to 77 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$251.2M
Full value: $251,203,493 · USD · 31 Mar 2026.$344.12M
Full value: $344,120,783 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 77 institutions filings for Q2 2026.
Security key
282564103
13F reference period
Q2 2026
13F holders
77
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
EIKN full holder history
Eikon Therapeutics, Inc. SEC filings
Eikon Therapeutics, Inc. company facts
Eikon Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 282564103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
EIKN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 10% | +11% | $49,350,159 | +$4,704,639 | 5,520,152 | +11% | FMR LLC | 30 Sep 2026 |
| Foresite Capital Fund IV, L.P. | 7.7% | 4,148,519 | James B. Tananbaum | 04 Feb 2026 | ||||
| BlackRock Portfolio Management LLC | 5.5% | $29,456,850 | 3,002,737 | BlackRock Portfolio Management LLC | 31 Mar 2026 | |||
| PERLMUTTER ROGER M | 5.2% | $28,555,598 | 2,893,171 | PERLMUTTER ROGER M | 04 Feb 2026 | |||
| Innovation Endeavors III LP | 5% | $26,878,241 | 2,723,226 | Innovation Endeavors III LP | 31 Mar 2026 | |||
| Abu Dhabi Investment Authority | 2.1% | -62% | $10,255,414 | -$14,926,009 | 1,147,138 | -59% | Abu Dhabi Investment Authority | 30 Sep 2026 |
As of 30 Jun 2026,
77
institutional investors reported holding
shares of
Eikon Therapeutics, Inc. - COMMON STOCK (EIKN).
This represents
49%
of the company’s total
outstanding shares.
26.49M
Full value: 26,490,842 · shares · 30 Jun 202654.12M
Full value: 54,119,137 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
46%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 9.2% | 4,993,906 | +30% | 0% | $65,170,473 |
| BlackRock, Inc. | 7.9% | 4,281,425 | +29% | 0% | $55,872,596 |
| Foresite Capital Management IV, LLC | 3.6% | 1,943,682 | 0% | 8.7% | $25,365,050 |
| Merck & Co., Inc. | 3.1% | 1,666,666 | 0% | 4.1% | $21,749,991 |
| T. Rowe Price Investment Management, Inc. | 2.9% | 1,595,274 | +30% | 0.01% | $20,819,000 |
| Foresite Capital Management V, LLC | 2.4% | 1,318,983 | 0% | 4.8% | $17,212,728 |
| Capital World Investors | 2.2% | 1,175,944 | +2.8% | 0% | $15,346,069 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.9% | 1,005,035 | +3% | 0% | $13,117,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7% | 922,707 | -4.8% | 0% | $12,041,326 |
| EcoR1 Capital, LLC | 1.4% | 732,606 | 0% | 0.47% | $9,560,508 |
| ALLIANCEBERNSTEIN L.P. | 1.2% | 641,888 | -37% | 0% | $6,791,175 |
| GEODE CAPITAL MANAGEMENT, LLC | 1% | 556,955 | +103% | 0% | $7,270,592 |
| BAKER BROS. ADVISORS LP | 1% | 555,555 | 0% | 0.04% | $7,249,993 |
| SOROS CAPITAL MANAGEMENT LLC | 0.9% | 484,672 | 0% | 1.1% | $6,324,969 |
| StepStone Group LP | 0.73% | 395,340 | 0% | 0.24% | $5,159,187 |
| CANADA PENSION PLAN INVESTMENT BOARD | 0.7% | 379,024 | 0% | 0% | $4,946,263 |
| STATE STREET CORP | 0.65% | 354,093 | +782% | 0% | $4,620,914 |
| FRANKLIN RESOURCES INC | 0.65% | 350,000 | 0% | 0% | $4,567,500 |
| General Catalyst Group Management, LLC | 0.56% | 305,233 | 0% | 2.1% | $3,983,291 |
| UBS Group AG | 0.49% | 263,932 | +166% | 0% | $3,444,313 |
| Parkman Healthcare Partners LLC | 0.47% | 256,053 | 0.34% | $3,341,492 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.34% | 182,105 | +39% | 0% | $2,376,470 |
| Schonfeld Strategic Advisors LLC | 0.33% | 179,775 | 0.01% | $2,346,063 | |
| NORTHERN TRUST CORP | 0.33% | 175,927 | +286% | 0% | $2,295,847 |
| Ensign Peak Advisors, Inc | 0.32% | 170,490 | -15% | 0% | $2,224,895 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Headline period
Q2 2026
Rows shown
1-3 of 3